Recent 8-K filings for SIGY

• February 20, 2026, 6:59 PM ET debt materiality 0.25 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements ×3

  Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount

  Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.

• August 15, 2025, 7:59 PM ET leadership materiality 0.80 negative item 1.01item 3.02item 5.02item 8.01item 9.01

  Three directors resign after D&O insurance lapse; $550K convertible note issued

  Directors Richa Nand, Michael Ryan, and Christopher Wetzel resigned on Aug 7-8, 2025 due to lapse of D&O coverage.

• March 7, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO

  CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.

• January 16, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

  Sigyn Therapeutics appoints Michael Ryan to board effective Jan 11, 2025

  Michael Ryan appointed to board; will serve until next stockholder meeting or successor elected.

• January 6, 2025, 6:59 PM ET other material materiality 0.50 neutral item 5.03item 9.01

  Sigyn Therapeutics reduces authorized common shares to 100M via charter amendment

  Filed Certificate of Amendment decreasing authorized common stock to 100 million shares (par value $0.0001).

• October 16, 2024, 7:59 PM ET other material materiality 0.50 neutral item 3.02

  Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase

  Corrected prior error: sellers were not controlled by an executive officer.

• October 16, 2024, 7:59 PM ET other material materiality 0.50 positive item 3.02

  Sigyn Therapeutics exchanges 246,259 warrants for 184,699 restricted shares; no warrants outstanding

  Exchanged 246,259 stock purchase warrants from 15 holders for 184,699 restricted common shares.

• October 7, 2024, 7:59 PM ET other material materiality 0.35 neutral item 3.02

  Sigyn Therapeutics issues 118,700 shares on conversion of $474,793 in debentures at $4.00/share

  Holders of $474,793 in convertible debentures converted at $4.00/share; 118,700 restricted shares issued.

• June 6, 2024, 7:59 PM ET other material materiality 0.35 neutral item 8.01

  Sigyn Therapeutics reports conversion of $226,903 in debentures at $6.00 per share, issuing 37,820 shares.

  Holders converted $226,903 of Original Issue Discount Senior Convertible Debentures at avg. exercise price of $6.00/share.

• May 15, 2024, 7:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  Sigyn Therapeutics files PCT patent for ImmunePrep platform to enhance antibody delivery for cancer treatment

  Filed PCT application US24/28579 on May 9, 2024 for 'DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES'.

• April 16, 2024, 7:59 PM ET debt materiality 0.70 neutral item 1.01 ◈ Material Agreements

  Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025

  Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.

Executive changes

Materiality & sentiment trend

Max materiality 0.80 · Median 0.50 · Most common event other_material

1 positive 1 negative 9 neutral

source · SIGY on sec.gov